SecurityGBL / GAMCO Investors, Inc. (361438104)
Chairman & CEOGABELLI MARIO J
IndustrySecurity Brokers, Dealers, and Flotation Companies
Institutional Owners85
Institutional Shares5,392,195 - 18.66%
Common Stock Shares Outstanding28,900,000 shares (as of 2018-03-31)
Institutional Value$ 154,384,000 USD
Related 36239YAB8 / Gabelli Asset Mgmt Inc Senior Notes 5.5% 05/15/13
361438AA2 / Gamco Investors Inc. 0% 12/31/15
361438AB0 / Gamco Investors Inc. 5.875% Senior Notes 06/01/21

Institutional Stock Ownership and Shareholders()

GBL / GAMCO Investors, Inc. Institutional Ownership

GAMCO Investors, Inc. (NYSE:GBL) has 85 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,392,195 shares. Largest shareholders include Gabelli Securities, Inc., Barr E S & Co, Vanguard Group Inc, BlackRock Inc., Dimensional Fund Advisors Lp, Royce & Associates LLC, State Street Corp, BlackRock Institutional Trust Company, N.A., Greenwich Wealth Management LLC, and FMR LLC / Fidelity.
GAMCO Investors, Inc. (NYSE:GBL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/gbl"><img src="https://images.fintel.io/us-gbl-so.png" alt="GBL / GAMCO Investors, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 50,822 12,475 -75.45 1,507 310 -79.43
2018-05-09 13F-HR ENVESTNET ASSET MANAGEMENT INC 117 117 0.00 4 3 -25.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 14,829 14,800 -0.20 440 368 -16.36
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,980 2,406 21.52 58 60 3.45
2018-05-11 13F-HR CITADEL ADVISORS LLC 14,965 372
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 23,473 24,058 2.49 696 598 -14.08
2018-05-15 13F-HR CSS LLC/IL 25,705 638
2018-05-10 13F-HR BEACH INVESTMENT COUNSEL INC/PA 11,888 11,888 0.00 352 295 -16.19
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 11,797 18,609 57.74 350 462 32.00
2018-07-11 13F-HR DENALI ADVISORS LLC 126 126 0.00 3 3 0.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 2,519 3,574 41.88 75 89 18.67
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 1,095 742 -32.24 32,466 18,424 -43.25
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 3,794 5,500 44.97 113 136 20.35
2018-05-08 13F-HR US BANCORP \DE\ 7,000 7,000 0.00 208 174 -16.35
2018-05-15 13F-HR HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 13,832 13,832 0.00 410 343 -16.34
2018-05-09 13F-HR NORTHERN TRUST CORP 66,309 98,629 48.74 1,966 2,449 24.57
2018-05-15 13F-HR BARR E S & CO 523,207 533,112 1.89 15,513 13,237 -14.67
2018-04-20 13F-HR FIRST QUADRANT L P/CA 16,658 0 -100.00 494 0 -100.00
2018-05-15 13F-HR Zebra Capital Management LLC 11,893 15,614 31.29 353 388 9.92
2018-07-18 13F-HR Jolley Asset Management, LLC 21,025 8,000 -61.95 522 214 -59.00
2018-05-17 13F-HR Legal & General Group Plc 1,298 893 -31.20 38 22 -42.11
2018-05-03 13F-HR Trexquant Investment LP 12,028 299
2018-05-14 13F-HR TEACHERS ADVISORS INC 6,509 0 -100.00 193 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 2,934 2,381 -18.85 87 59 -32.18
2018-05-14 13F-HR FMR LLC / Fidelity 100,060 130,160 30.08 2,967 3,232 8.93
2018-04-25 13F-HR RICE HALL JAMES & ASSOCIATES, LLC 70,658 23,219 -67.14 2,095 577 -72.46
2018-07-10 13F-HR MIDAS MANAGEMENT CORP 78,777 78,777 0.00 1,956 2,108 7.77
2018-05-15 13F-HR Advisor Group, Inc. 15 15 0.00 0 0
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 167,858 258,582 54.05 4,977 6,421 29.01
2018-05-03 13F-HR Wellington Shields Capital Management, LLC 0 11,750 0 292
2018-05-16 13F-HR Israel Discount Bank of New York 545 545 0.00 16 14 -12.50
2018-05-14 13F-HR S. MUOIO & CO. LLC 51,444 66,444 29.16 1,525 1,650 8.20
2017-10-26 13F-HR Acrospire Investment Management LLC 660 0 -100.00 20 0 -100.00
2018-05-03 13F-HR SG Americas Securities, LLC 4,911 0 -100.00 146 0 -100.00
2018-05-01 13F-HR NEW YORK STATE TEACHERS RETIREMENT SYSTEM 400 0 -100.00 12 0 -100.00
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 11,166 11,166 0.00 331 277 -16.31
2018-05-22 13F-HR/A Summit Trail Advisors, Llc 3,697 0 -100.00 110 0 -100.00
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 19,185 19,285 0.52 569 479 -15.82
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 1,175 1,187 1.02 35 29 -17.14
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 9,524 0 -100.00 282 0 -100.00
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 14,506 13,989 -3.56 430 347 -19.30
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 19,741 22,014 11.51 585 546 -6.67
2018-05-09 13F-HR BlackRock Inc. 338,505 386,108 14.06 10,036 9,587 -4.47
2018-04-26 13F-HR DUNCKER STREETT & CO INC 4,000 4,000 0.00 119 99 -16.81
2018-05-15 13F-HR BARCLAYS PLC 815 1,365 67.48 24 34 41.67
2018-05-15 13F-HR STATE STREET CORP 115,832 196,276 69.45 3,434 4,876 41.99
2018-05-15 13F-HR Bank of New York Mellon Corp 75,602 69,675 -7.84 2,242 1,730 -22.84
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 12,091 16,117 33.30 358 400 11.73
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 6,629 9,078 36.94 197 226 14.72
2018-05-11 13F-HR Delpha Capital Management, Llc 100 0 -100.00 3 0 -100.00
2018-05-15 13F-HR Horizon Kinetics LLC 91,577 85,971 -6.12 2,715 2,134 -21.40
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 75 75 0.00 2 2 0.00
2018-05-15 13F-HR VANGUARD GROUP INC 289,825 453,175 56.36 8,593 11,253 30.96
2018-05-02 13F-HR Greenwich Wealth Management LLC 50,800 160,093 215.14 1,506 3,975 163.94
2017-03-16 13F-HR ISRAEL DISCOUNT BANK OF NEW YORK /GFN 570 18
2018-05-10 13F-HR JP Morgan Chase & Co 34,255 30,937 -9.69 1,016 768 -24.41
2018-05-14 13F-HR AUXIER ASSET MANAGEMENT 7,950 9,950 25.16 236 247 4.66
2018-05-09 13F-HR GABELLI SECURITIES, INC. 2,193,055 1,526,250 -30.41 65,024 37,897 -41.72
2018-07-20 13F-HR MCF Advisors LLC 1,000 1,000 0.00 25 27 8.00
2018-05-09 13F-HR CIGNA INVESTMENTS INC /NEW 9,560 0 -100.00 284 0 -100.00
2018-05-04 13F-HR STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 6,845 0 -100.00 203 0 -100.00
2018-05-14 13F-HR Stone Ridge Asset Management LLC 16,976 16,976 0.00 503 422 -16.10
2018-05-15 13F-HR DEUTSCHE BANK AG\ 58,166 13,910 -76.09 1,722 344 -80.02
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 19,346 14,965 -22.65 574 372 -35.19
2017-02-10 13F-HR BlackRock Investment Management, LLC 21,173 21,260 0.41 603 657 8.96
2018-05-11 13F-HR Covington Capital Management 203 203 0.00 6 5 -16.67
2018-05-14 13F-HR Royce & Associates LLC 243,873 243,898 0.01 7,231 6,056 -16.25
2017-08-18 13F-HR WFG Advisors, LP 52 75 44.23 2 2 0.00
2018-05-14 13F-HR PRICE MICHAEL F 16,500 47,000 184.85 489 1,167 138.65
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 4,900 4,900 0.00 145 122 -15.86
2017-02-10 13F-HR BlackRock Fund Advisors 112,601 128,957 14.53 3,206 3,983 24.24
2018-05-11 13F-HR MARTINGALE ASSET MANAGEMENT L P 26,817 26,811 -0.02 796 666 -16.33
2018-05-04 13F-HR Swiss National Bank 8,543 9,338 9.31 253 232 -8.30
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 7,482 0 -100.00 222 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 94,000 19,500 -79.26 2,787 484 -82.63
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 36,479 36,023 -1.25 1,081 894 -17.30
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 3,899 5,606 43.78 116 139 19.83
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 10,000 10,000 0.00 297 248 -16.50
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 170,053 162,151 -4.65 4,841 5,009 3.47
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 3,382 8,286 145.00 100 206 106.00
2017-02-10 13F-HR BlackRock Advisors LLC 2,586 2,449 -5.30 74 76 2.70
2017-02-10 13F-HR BlackRock Group LTD 1,297 1,297 0.00 37 40 8.11
2018-04-23 13F-HR Advisory Services Network, LLC 6,683 6,405 -4.16 198 159 -19.70
2018-05-02 13F-HR FTB Advisors, Inc. 149 149 0.00 4 3 -25.00
2018-05-14 13F-HR MORGAN STANLEY 51,649 59,193 14.61 1,531 1,469 -4.05
2018-05-15 13F-HR TWO SIGMA ADVISERS, LP 24,697 29,827 20.77 732 741 1.23
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 33,707 37,141 10.19 999 922 -7.71
2018-05-15 13F-HR UBS Group AG 380 591 55.53 12 15 25.00
2018-04-17 13F-HR Guinness Asset Management Ltd 3,000 3,000 0.00 89 74 -16.85
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 1,985 2,101 5.84 59 52 -11.86
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 629 629 0.00 18 15 -16.67
2018-05-15 13F-HR Brandywine Global Investment Management, LLC 31,733 30,279 -4.58 941 752 -20.09
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 27 56 107.41 1 2 100.00
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 3,019 3,329 10.27 90 83 -7.78
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 7,303 7,931 8.60 217 197 -9.22
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 342 342 0.00 10 8 -20.00
2018-05-11 13F-HR Russell Investments Group, Ltd. 23,390 23,390 0.00 699 580 -17.02

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

Mario Gabelli: We'll Use The Same Guiding Principles To Avoid Over-Paying For A Company's Intrinsic Value And Lose Less During Market Manias

2018-07-20 valuewalkpremium
One of the investors we follow closely here at The Acquirer’s Multiple is Mario Gabelli, Founder, Chairman and CEO of GAMCO Investors, Inc. Gabelli recently did a Q&A session with some folks at Reddit which provided some great value investing insights. Here’s an except from the thread on Reddit:

Mario Gabelli On Disney And Comcast's Battle For Fox Assets

2018-06-21 valuewalk
Mario Gabelli, Gamco Investors chairman and CEO, weighs in on the media landscape as Disney and Comcast wage a bidding war over Fox assets. (2-0)

Disney hikes bid for Fox assets to $71.3 billion, tops Comcast

2018-06-21 moneycontrol
Walt Disney Co raised its bid for the bulk of Twenty-First Century Fox Inc's film and television assets to $71.3 billion on Wednesday, sweetening its deal with cash as it looks to upend Comcast Corp's $65 billion offer. (89-0)

With Two Suitors for Fox, the Murdochs Consider Next Steps - The New York Times

2018-06-20 nytimes
The Walt Disney Company has agreed to buy most of 21st Century Fox’s assets in a deal worth $52.4 billion, but things got complicated last week when Comcast made a rival offer that valued the business at $65 billion. (19-0)

Billionaire Investor Mario Gabelli On The AT&T-Time Warner Merger

2018-06-18 valuewalk
Mario Gabelli, Gamco Investors chairman and CEO, speaks with CNBC’s “Squawk Box” about his take on the mega-merger between AT&T and Time Warner. (4-0)

CUSIP: 361438104